An interventional study of Subcutaneous Daratumumab Administration Using FreedomEDGE® in Multiple Myeloma or Amyloidosis, sponsored by Hospices Civils de Lyon. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 376 studies in Multiple Myeloma with a site in France — 72 open to participants now, 136 under way, 48 of them phase 3. Multiple Myeloma · France.
Among the 376 studies in Multiple Myeloma with a site in France, this one is the 184th largest by planned enrollment of the 315 interventional ones that give a count, is one of 21 that started in 2026, is one of 33 with no phase, reaches primary completion later than 62 of the 135 other live ones, and was the 375th registered.
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →72 of the 376 studies in Multiple Myeloma with a site in France are open now. Recruiting first, the newest first:
AstraZeneca · Sites in France, United States, Australia and 15 more countries
Ages 18–130
CSL Behring · Sites in France, United States, Belgium and 8 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in France, Australia, Czechia and 11 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in France, United States, Argentina and 7 more countries
Ages 18+
AstraZeneca · Sites in France, United States, Australia and 12 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
376 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 94 · Phase 2 116 · Phase 3 107 · Phase 4 2
First in 1997; this study’s year is marked. 21 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 41 across 3,009 interventional studies indexed under Multiple Myeloma.
Median enrollment 137 across the 315 interventional studies, 203 across the 60 observational. Of the 221 that completed or were terminated, 85 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
231 of 376 have an industry lead sponsor. The 10 most frequent:
Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.
Hospices Civils de Lyon has 5 studies filed under Multiple Myeloma — fewer than ten, so there is no comparison to draw.
29 of the studies in Multiple Myeloma with a site in France that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05519085Phase 3CelgeneA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-01-10 |
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT05455320Phase 3Janssen Research & Development, LLCA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | 2027-07-30 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT05317416Phase 3PfizerStudy With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | 2027-08-04 |
Add all 29 to your calendar (.ics) → With an account.
Among the 376 studies in Multiple Myeloma with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is evaluating a new method for administering daratumumab, a treatment commonly used in the management of multiple myeloma and amyloidosis. For several years, this treatment has been administered by subcutaneous injection in just a few minutes, significantly reducing the amount of time patients spend in hospital. Currently, this injection is performed manually by nurses. Although effective, this method may be demanding in daily practice due to the repetitive nature of the procedure and the physical workload involved for healthcare professionals.
The aim of this study is to evaluate a medical device called FreedomEDGE®, developed by KORU Medical Systems, which enables mechanical and automated subcutaneous administration of daratumumab. This device operates without electricity: a spring-based system applies constant pressure to a syringe in order to deliver the medication steadily through a subcutaneous needle. This type of equipment is already used for the administration of other subcutaneous treatments, like immunoglobulins.
The primary objective of the study is to assess whether this device enables safe and effective administration of the treatment. Secondary objectives include evaluating administration time, identifying potential technical malfunctions, describing the occurrence of local or systemic adverse events, and assessing the experience and satisfaction of both patients and nurses using the device.
For patients, the expected benefits include more consistent and controlled administration, potential improvement in injection comfort, and a smoother care experience. For healthcare professionals, this approach may help to reduce the burden associated with repeated injections, improve working conditions, and support more efficient organisation of care in the day hospital setting.
This study will be conducted in the daily hospitalisation unit of the Clinical Hematology Department at Lyon Sud Hospital and will include approximately 100 patients with multiple myeloma or amyloidosis receiving subcutaneous daratumumab. Participation is fully integrated into routine care. Patients who agree to participate will sign an informed consent form before any study-specific procedures are carried out.
The treatment administered will remain exactly the same as that planned as part of routine care; only the method of administration will change, with one injection being delivered using the FreedomEDGE® device. An additional clinical assessment will be performed before administration to confirm that there are no contraindications to injection. After administration, patients will be asked to complete a short questionnaire regarding their experience and satisfaction, and nurses will also complete a questionnaire about their experience using the device.
No additional blood samples, no additional medication, and no specific restrictions regarding usual treatments are planned as part of this study. Participation will end after the visit corresponding to the injection performed using the device. At any time, the investigator may discontinue participation if considered necessary for patient safety or in the patient's medical interest.
This clinical investigation is designed to generate clinical evidence supporting evaluation of the performance and safety of the FreedomEDGE® Infusion System for subcutaneous (SC) administration of daratumumab.
Daratumumab is a human IgG1κ monoclonal antibody directed against CD38 and approved for the treatment of multiple myeloma. The availability of a subcutaneous formulation has substantially reduced administration time compared with intravenous infusion while maintaining therapeutic effectiveness and improving treatment convenience. The approved SC formulation is administered continuously over approximately 3-5 minutes.
In routine clinical practice, SC administration of daratumumab requires nurses to manually apply continuous pressure to the syringe plunger throughout the injection period in order to maintain administration conditions consistent with the approved product labelling. This manual procedure may introduce variability in injection duration and administration consistency and may contribute to patient discomfort, local injection-site reactions, and repetitive physical strain for healthcare professionals.
The FreedomEDGE® Infusion System is a mechanical, non-electrical infusion device intended for controlled subcutaneous administration of medicinal products. The system combines a reusable infusion pump with sterile precision flow tubing and sterile High-Flo™ SubQ needle sets. Drug delivery is achieved through a constant-force spring mechanism associated with dedicated flow restriction tubing selected according to product viscosity and administration conditions.
Although the device currently bears CE marking for selected approved subcutaneous therapies, administration of daratumumab is not currently included within its intended purpose.
This clinical investigation is conducted within the framework of Regulation (EU) 2017/745 on medical devices (MDR) as a clinical investigation intended to establish conformity of a CE-marked device used outside its currently approved intended purpose, with the objective of supporting extension of CE marking. According to applicable European and national regulatory classification criteria, this investigation corresponds to regulatory category 1.
This is a prospective, single-centre, non-randomized clinical investigation conducted in the Clinical Hematology Department of Lyon-Sud hospital (Pierre-Bénite, France).
The primary objective is to evaluate the performance of the FreedomEDGE® Infusion System for subcutaneous administration of daratumumab.
Device performance is defined as the ability to provide reliable, controlled, and complete administration of the prescribed dose under normal conditions of use and according to the device instructions for use.
Eligible participants must be adults, diagnosed of multiple myeloma or light-chain amyloidosis; treated with monthly subcutaneous daratumumab.
Participants are recruited among patients routinely followed in the Clinical Hematology Department and receiving daratumumab in the day hospital setting. Enrolment occurs once treatment reaches the monthly administration phase, corresponding to patients who have already received several prior manual SC injections and therefore have prior experience with standard administration.
Approximately 100 evaluable administrations are planned. Based on expected routine activity and patient flow, recruitment is expected to be completed over approximately six months.
At Screening and Inclusion time (T0), potential participants are identified during routine follow-up within the hematology department. Patients whose daratumumab schedule reaches monthly administration are informed about the study by a physician co-investigator. Patients receive oral and written information describing study objectives, procedures, constraints, potential risks, safety measures, and participant rights, including the right to refuse participation or withdraw consent at any time without impact on standard care. Written informed consent is obtained before any study-specific procedure. Eligibility criteria are subsequently verified in full before formal enrolment. Clinical evaluation at inclusion is limited to routine assessment and observation of the future injection site.
The study intervention is performed at the participant's next scheduled monthly administration visit (M1). Subcutaneous daratumumab is administered using the FreedomEDGE® Infusion System according to the device instructions for use and following nurse training.
Administration is performed using a prefilled daratumumab syringe connected to dedicated precision flow tubing (reference F1200) and a sterile High-Flo™ SubQ needle set (24G, 9 mm). After skin preparation and placement of the needle, the syringe is loaded into the device and administration is initiated.
Following administration, the following data are collected: device traceability information; administration duration; total injected volume compared with prescribed volume; occurrence and description of any device malfunction; corrective actions implemented to complete administration if required; occurrence of local skin reactions; occurrence of systemic adverse events.
Following administration, nurses complete a study-specific questionnaire assessing: pain associated with administration; ease of use; ease of injection; device reliability; overall satisfaction; preference between manual administration and device-assisted administration; interest in extending use of the system to other therapies. Patients complete a study-specific questionnaire assessing: injection experience; comfort; satisfaction; preference between manual administration and device-assisted administration.
Questionnaires are completed shortly after administration and require approximately five minutes.
The end-of-study visit corresponds to the M1 administration visit. Participant follow-up ends after completion of this visit.
No biological samples are collected specifically for study purposes. No additional visits, laboratory tests, imaging procedures, or invasive assessments are required beyond standard care.
Expected benefits for patients include more standardized and controlled administration, improved injection comfort, and reduction of injection-related discomfort. Expected benefits for healthcare professionals include reduced physical strain associated with repeated manual injections and improved working conditions.
Risks associated with device use are expected to remain comparable to routine subcutaneous administration and include administration error, contamination, injection-site trauma, and local reactions such as redness, swelling, or pain. Appropriate monitoring and risk mitigation procedures are implemented throughout the study. In case of device malfunction, administration may be completed manually according to standard practice.
Overall, considering the anticipated improvements in administration standardization and user experience together with the limited and controlled risks associated with the procedure, the expected benefit-risk profile is considered favourable.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive their planned subcutaneous daratumumab treatment as part of routine clinical care. The investigational intervention consists solely of administering daratumumab using the FreedomEDGE® mechanical infusion system instead of the standard manual nurse-administered injection. FreedomEDGE® is a non-electric infusion device that uses a spring mechanism to apply constant pressure to a syringe, enabling controlled and continuous subcutaneous delivery of the drug through a subcutaneous needle connected by tubing. Prior to administration, an additional clinical assessment will be performed to confirm the absence of contraindications. Following treatment administration, patients will complete a short questionnaire evaluating their experience and satisfaction, and nurses will complete a questionnaire regarding usability and their experience with the device.
Device: Subcutaneous Daratumumab Administration Using FreedomEDGE®
Participants will receive a single administration of subcutaneous daratumumab using the FreedomEDGE® mechanical infusion system during a routine scheduled treatment visit. The medicinal product, dose, indication, and standard clinical management remain unchanged and follow usual care. The intervention consists exclusively of replacing the standard manual nurse-administered subcutaneous injection with device-assisted administration. FreedomEDGE® is a non-electric mechanical infusion device that uses a spring-driven mechanism to apply constant pressure to a prefilled syringe, enabling controlled and continuous delivery of daratumumab through a subcutaneous needle connected by tubing. Prior to administration, a brief clinical assessment will confirm the absence of contraindications to treatment administration. No additional procedures, medications, or biological sampling are planned as part of the intervention.
Delivery Success Rate of Device-Assisted Subcutaneous Daratumumab Administration
Performance will be assessed by the proportion of system-assisted subcutaneous administrations achieving complete delivery (100%) of the prescribed 15 mL dose without device-related malfunction or unplanned manual intervention (delivery success).
Time frame: Month 1, at the end of the procedure
Subcutaneous Daratumumab Administration Duration (minutes)
Daratumumab injection duration (in minutes)
Time frame: Month 1, at the end of the procedure
Number of malfunction occuring
Number of malfunction occurence
Time frame: Month 1, at the end of the procedure
Type of malfunctions occuring
Type of malfunctions occurence
Time frame: Month 1, at the end of the procedure
Recourse methods in case of malfunction
Description of recourse methods implemented to ensure that the injection is carried out in its entirety following malfunctions
Time frame: Month 1, at the end of the procedure
Skin or systemic events
Occurrence of at least one skin reaction or systemic event
Time frame: within 5 minutes of end of administration
Number of reactions
Number of reactions per patient
Time frame: within 5 minutes of end of administration
Type of reactions
Type of reactions (at puncture point or generalized)
Time frame: within 5 minutes of end of administration
Grade of reactions
Grade of reactions (according to CTCAE)
Time frame: within 5 minutes of end of administration
Accountability of adverse reaction
Count of adverse reactions related to the device
Time frame: Month 1, at the end of the procedure
Nurses Pain scale
Score obtained on a pain scale (VAS from 0 to 10)
Time frame: within 5 minutes of end of administration
Nurses repetitiveness felt
The repetitiveness of nurse gesture (scores obtained on a scale developed by the hematology department)
Time frame: Month 1, at the end of the day, post-use of the infusion system for each nurse
Nurses ease of installation and connection felt
The ease of installation and connection for nurse (scores obtained on a scale developed by the hematology department)
Time frame: Month 1, at the end of the day, post-use of the infusion system for each nurse
Nurses ease of injection felt
The ease of injection for nurses (scores obtained on a scale developed by the hematology department)
Time frame: Month 1, at the end of the day, post-use of the infusion system for each nurse
Nurses system reliability felt
The system reliability felt for nurses (scores obtained on a scale developed by the hematology department)
Time frame: Month 1, at the end of the day, post-use of the infusion system for each nurse
Nurses perception of patient comfort
Nurses perception of patient comfort (scores obtained on a scale developed by the hematology department)
Time frame: Month 1, at the end of the day, post-use of the infusion system for each nurse
Nurses overall satisfaction
Score of Nurses overall satisfaction with a Lickert scale
Time frame: Month 1, at the end of the day, post-use of the infusion system for each nurse
Nurses preference system
Expression of the preference of the injection system thanks to the DM compared to the classic manual method
Time frame: Month 1, at the end of the day, post-use of the infusion system for each nurse
Patients feeling about comfort
Score obtained on a likert scale
Time frame: 5 minutes after completion of injection
Patients global satisfaction
Score obtained on a likert scale
Time frame: 5 minutes after completion of injection
Patients preference
Expression of the preference of the injection system using medical device compared with the manual method
Time frame: 5 minutes after completion of injection
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for May 2027, 7 months later.
Of 172 non-industry interventional studies with no phase under Multiple Myeloma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 81. This study's planned 7 months is below that.
Counting every sponsor, half of 186 studies reached it within 38 months; a quarter within 20 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.